Predictive value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting lymph node metastasis in endometrial cancer

Main Article Content

Razieh Vejdani
Manizheh Sayyah-Melli
Mehri Jafari Shobeiri
Parvin Mostafa Gharebaghi
Vahideh Rahmani
Maryam Vaezi

Keywords

Endometrial carcinoma, metastasis to lymph nodes, neutrophil to lymphocyte, platelet to lymphocyte ratio

Abstract

Background: Predicting lymph node metastasis in endometrial cancer patients is one of the most critical elements in assessing disease prognosis and selecting whether to undertake lymphadenectomy. There is limited and contradictory information about the predictive efficacy of neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratio in predicting lymph node metastasis.The purpose of the present study was to evaluate the predictive efficacy of preoperative neutrophil and platelet-to-lymphocyte ratios for predicting lymph node metastases in endometrial cancer patients.
Materials and methods: This retrospective study was conducted on the medical records of endometrial carcinoma patients treated at Al-Zahra Hospital in Tabriz with gynecological cancers in between 2016 -2020. Demographic data including age, initial symptoms, history of cancer, chemotherapy, serum Cancer Antigen 125 (CA125) level, pre-operative level of complete blood count (CBC), white blood cells (WBCs), neutrophils, lymphocytes, monocytes, hemoglobin, curettage result, and cancer surgery stage were extracted from patient’s files. We utilized the receiver operating characteristic curve (ROC) to calculate the optimal value of the cut-off point for NLR and PLR. All analyses were conducted using Statistical Package for the Social Sciences (SPSS) 26.
Results: From the total of 131 participants, More than two third histopathological subtype was endometrioid endometrial carcinoma [73.0%]. The ROC curve revealed that the cut-off for NLR and PLR was 2.47 and 62.67, respectively. The rising trend of NLR is a prognostic marker for lymphatic metastasis, according to a logistic regression analysis [hazard ratio = 1.20; 95% [CI], 1.5-2.3; P = 0.001]. Although the rising trend of PLR was associated with an increased risk of lymph node metastasis, it has no significant predictive value in the present model P= 0.1]
Conclusion: The rising trend of NLR can be utilized as an independent predictor of lymphatic metastasis in women with endometrial cancer and can aid clinicians in pre-operative risk stratification and treatment strategy.

Abstract 141 | PDF Downloads 117

References

1. Akhtar M, Al Hyassat S, Elaiwy O, Rashid S, Al-Nabet ADMH. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology. Adv Anat Pathol. 2019 Nov;26[6]:421-427
2. Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients. Oncology. 2019;96[5]:259-267.
3. Ballester M, Canlorbe G, Cortez A, Gonin J, Laas E, Bendifallah S, et al. Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecol Oncol. 2013 Sep;130[3]:457-62.
4. Bogani G, Murgia F, Ditto A, Raspagliesi F. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2019 Jun;153[3]:676-683.
5. Bougherara L, Azaïs H, Béhal H, Canlorbe G, Ballester M, Bendifallah S, et al.. Does lymphadenectomy improve survival in patients with intermediate risk endometrial cancer? A multicentric study from the FRANCOGYN Research Group. Int J Gynecol Cancer. 2019 Feb;29[2]:282-289
6. Clarke SJ, Chua W, Moore M, Kao S, Phan V, Tan C, et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011 Sep;90[3]:475-8.
7. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31[1]:12-39.
8. Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020 May 24;20[1]:464.
9. Constantine GD, Kessler G, Graham S, Goldstein SR. Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors. J Womens Health [Larchmt]. 2019 Feb;28[2]:237-243.
10. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 Apr 9;399[10333]:1412-1428.
11. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K et al Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer. 2015 Jul 14;113[2]:311-20.
12. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio [NLR] and Platelet-to-Lymphocyte ratio [PLR] as prognostic markers in patients with non-small cell lung cancer [NSCLC] treated with nivolumab. Lung Cancer. 2017 Sep;111:176-181.
13. Dong Y, Cheng Y, Wang J. The Ratio of Neutrophil to Lymphocyte is a Predictor in Endometrial Cancer. Open Life Sci. 2019 Apr 6;14:110-118.
14. Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, Zhang C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021 May;161[2]:573-580.
15. Helgers RJA, Winkens B, Slangen BFM, Werner HMJ. Lymphedema and Post-Operative Complications after Sentinel Lymph Node Biopsy versus Lymphadenectomy in Endometrial Carcinomas-A Systematic Review and Meta-Analysis. J Clin Med. 2020 Dec 31;10[1]:120. 16. Huvila J, Pors J, Thompson EF, Gilks CB. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. J Pathol. 2021 Apr;253[4]:355-365.
17. Ilgen O, Kurt S, Yuzuguldu RI, Ada O, Mankan A. Platelet to lymphocyte and neutrophil to lymphocyte ratios in endometrial pathologies. Ginekol Pol. 2022 Jan 24.
18. Kim EY, Lee JW, Yoo HM, Park CH, Song KY. The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer? Ann Surg Oncol. 2015 Dec;22[13]:4363-70.
19. Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Taib NA. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015 Jun 30;113[1]:150-8.
20. Kim, J. Y., Jung, E. J., Kim, J. M., Lee, H. S., Kwag, S. J., Park, J. H, et al.. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC cancer, (2020). 20(1), 1-8.
21. LeBental A. Lymph Node Dissection for Uterine Cancer is Associated With a Higher Incidence of Venous Thromboembolism [A112]. Obstetrics & Gynecology. 2022 May 1;139(1):33S.
22. Lee JW, Seol KH. Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer. J Clin Med. 2021 May 19;10[10]:2199.
23. Leitao MM Jr, Zhou QC, Gomez-Hidalgo NR, Iasonos A, Baser R, Mezzancello M, et al. Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecol Oncol. 2020 Jan;156[1]:147-153.
24. McLaren PJ, Bronson NW, Hart KD, Vaccaro GM, Gatter KM, et al.. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer. J Gastrointest Surg. 2017 Apr;21[4]:607-613.
25. Salzano, G., Dell’Aversana Orabona, G., Abbate, V., Vaira, L. A., Committeri, U., Bonavolontà, et al.. The prognostic role of the pre-treatment neutrophil to lymphocyte ratio (NLR) and tumor depth of invasion (DOI) in early-stage squamous cell carcinomas of the oral tongue. Oral and Maxillofacial Surgery (2022)., 26(1), 21-32.
26. Mitamura T, Watari H, Todo Y, Kato T, Konno Y, Hosaka M, et al. Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments. J Gynecol Oncol. 2014 Oct;25[4]:301-5.
27. Pölcher M, Rottmann M, Brugger S, Mahner S, Dannecker C, Kiechle M, Brambs C, et al. Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients. Gynecol Oncol. 2019 Jul;154[1]:65-71.
28. Reijnen C, IntHout J, Massuger LFAG, Strobbe F, Küsters-Vandevelde HVN, Haldorsen IS, et al. Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis. Oncologist. 2019 Sep;24[9]:e880-e890.
29. Rostami S, Nahvijou A. Gynecologic Cancers Statistics in the IR Iran in 2020. Basic & Clinical Cancer Research. 2021;13[2]:111-8.
30. Sargazi N, Daroudi R, Zendehdel K, Hashemi FA, Tahmasebi M, Darrudi A, et al. Economic Burden of Gynecological Cancers in Iran. Value Health Reg Issues. 2022 Mar;28:1-6.
31. Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R, et al. Pathologic Prognostic Factors in Endometrial Carcinoma [Other Than Tumor Type and Grade]. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1[Iss 1 Suppl 1]:S93-S113.
32. Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1[Iss 1 Suppl 1]:S64-S74.
33. Stojkovic Lalosevic M, Pavlovic Markovic A, Stankovic S, Stojkovic M, Dimitrijevic I, Radoman Vujacic I, Lalic D, Milovanovic T, Dumic I, Krivokapic Z. Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio [NLR], Platelet-to-Lymphocyte Ratio [PLR], and Mean Platelet Volume [MPV] as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer. Dis Markers. 2019 Jan 17;2019:6036979.
34. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, et al. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 Jul;132[1]:52-58.
35. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013;14[9]:5237-42.
36. Ural ÜM, Şehitoğlu İ, Tekin YB, Şahin FK. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015 Mar;41[3]:445-8.
37. Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology: JB Lippincott; 1863.
38. Yavuzcan A, Bakay K. Prophylactic ligation of uterine arteries at its origin in laparoscopic surgical staging for endometrial cancer. J Obstet Gynaecol Res. 2021 Dec;47[12]:4381-4388.